776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study

• James Larkin,
• Harriet Kluger,
• Omid Hamid,
• Jeffrey Weber,
• Amod A Sarnaik,
• Brian Gastman,
• Jeffrey Chou,
• John M Kirkwood,
• Eric Whitman,
• Martin Wermke,
• Evidio Domingo-Musibay,
• Theresa Medina,
• Sajeve Thomas,
• Wen Shi,
• Xiao Wu,
• Jason A Chesney,
• Giri Sulur,
• Friedrich Graf Finckenstein

Affiliations

James Larkin

Royal Marsden Hospital, London, UK

Harriet Kluger

2Yale Smilow Cancer Center, New Haven, CT, USA

Omid Hamid

3The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA

Jeffrey Weber

14NYU Langone Medical Center, New York, NY, USA

Amod A Sarnaik

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Brian Gastman

Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA

Jeffrey Chou

Aff15 grid.417886.40000000106575612Amgen Inc. Thousand Oaks CA USA

John M Kirkwood

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Eric Whitman

Aff6 grid.416113.00000000097594781Carol G. Simon Cancer Center Morristown NJ USA

Martin Wermke

3Technical University Dresden – NCT/UCC Early Clinical Trial Unit, Dresden, Germany

Evidio Domingo-Musibay

Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA

Theresa Medina

9University of Colorado, Aurora, CO, USA

Sajeve Thomas

5Orlando Health Cancer Institute, Orlando, FL, USA

Wen Shi

15Iovance Biotherapeutics, San Carlos, CA, USA

Xiao Wu

16Iovance Biotherapeutics, Inc., San Carlos, CA, USA

Jason A Chesney

1 J. Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA

Giri Sulur

Iovance Biotherapeutics Inc, San Carlos, California, USA

Friedrich Graf Finckenstein

12Iovance Biotherapeutics, Inc, San Carlos, CA, USA